Some uses of transition metal complexes as anti-cancer and anti-HIV agents.

The success of the clinical uses of cisplatin, cis-[Pt(II)(NH(3))(2)Cl(2)], has stimulated considerable interest in using other metal complexes as new therapeutic agents. This perspective describes our recent work on several classes of gold(III), platinum(II), ruthenium(II, III, IV), iron(II) and vanadium(IV) complexes for anti-cancer and anti-HIV treatments.

[1]  P. Sadler,et al.  Cyclam complexes and their applications in medicine. , 2004, Chemical Society reviews.

[2]  R. Schinazi,et al.  Anti-HIV-1 activity, toxicity, and stability studies of representative structural families of polyoxometalates. , 1990, Journal of medicinal chemistry.

[3]  M. Franchini,et al.  Iron-chelation therapy: an update. , 2004, The hematology journal : the official journal of the European Haematology Association.

[4]  M J Clarke,et al.  Non-platinum chemotherapeutic metallopharmaceuticals. , 1999, Chemical reviews.

[5]  R. Buckley,et al.  Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes. , 1996, Journal of medicinal chemistry.

[6]  M. Battell,et al.  Vanadium compounds as insulin mimics. , 1999, Metal ions in biological systems.

[7]  L. Ronconi,et al.  Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes. , 2005, Journal of medicinal chemistry.

[8]  C. Che,et al.  Cyclometallated platinum(II) complexes as luminescent switches for calf-thymus DNA , 1996 .

[9]  C. Che,et al.  Application of 2,6-diphenylpyridine as a tridentate [C∧N∧C] dianionic ligand in organogold(III) chemistry. structural and spectroscopic properties of mono- and binuclear transmetalated gold(III) complexes , 1998 .

[10]  M. Abrams,et al.  Metal compounds in therapy and diagnosis. , 1993, Science.

[11]  C. Che,et al.  A mixed-valent ruthenium-oxo oxalato cluster Na7[Ru4(mu3-O)4(C2O4)6] with potent anti-HIV activities. , 2006, Journal of the American Chemical Society.

[12]  O. D'cruz,et al.  Spermicidal activity of metallocene complexes containing vanadium(IV) in humans. , 1998, Biology of reproduction.

[13]  Jian Ding,et al.  Novel Au(III) complexes of aminoquinoline derivatives: crystal structure, DNA binding and cytotoxicity against melanoma and lung tumour cells , 2003 .

[14]  Qing‐Yu He,et al.  Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug , 2006, Proteomics.

[15]  L. Messori,et al.  Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. , 2002, Journal of medicinal chemistry.

[16]  G. Arena,et al.  SYNTHESIS CHARACTERIZATION, AND INTERACTION WITH DNA OF THE NOVEL METALLOINTERCALATOR CATIONIC COMPLEX (2,2':6',2 -TERPYRIDINE)METHYLPLATINUM(II) , 1995 .

[17]  Di Chen,et al.  A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. , 2006, Cancer research.

[18]  S. Lippard,et al.  New metal complexes as potential therapeutics. , 2003, Current opinion in chemical biology.

[19]  K. Lee,et al.  Anti-HIV and cytotoxic activities of Ru(II)/Ru(III) polypyridyl complexes containing 2,6-(2'-benzimidazolyl)-pyridine/chalcone as co-ligand. , 2001, Bioorganic & medicinal chemistry.

[20]  C. Che,et al.  Anticancer Cyclometalated [AuIIIm(C∧N∧C)mL]n+ Compounds: Synthesis and Cytotoxic Properties , 2006 .

[21]  M. Abrams,et al.  Medicinal inorganic chemistry: introduction. , 1999, Chemical reviews.

[22]  A. Eastman.  The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. , 1987, Pharmacology & therapeutics.

[23]  J. Stubbe,et al.  Mechanisms of bleomycin-induced DNA degradation , 1987 .

[24]  Hongzhe Sun,et al.  Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. , 2003, Chemical communications.

[25]  K. Thompson.  Coordination chemistry of vanadium in metallopharmaceutical candidate compounds , 2001 .

[26]  M. Otto,et al.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication , 1997, Antimicrobial agents and chemotherapy.

[27]  J. Barton,et al.  On demonstrating DNA intercalation , 1990 .

[28]  F. Uckun,et al.  Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2003, Biochemical and biophysical research communications.

[29]  J. Stubbe,et al.  Solution structure of Co(III)-bleomycin-OOH bound to a phosphoglycolate lesion containing oligonucleotide: implications for bleomycin-induced double-strand DNA cleavage. , 2001, Biochemistry.

[30]  R Abagyan,et al.  Flexible protein–ligand docking by global energy optimization in internal coordinates , 1997, Proteins.

[31]  P. Sadler.  Inorganic Chemistry and Drug Design , 1991 .

[32]  A. Casini,et al.  Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. , 2006, Journal of medicinal chemistry.

[33]  F. Uckun,et al.  Apoptosis-inducing vanadocene compounds against human testicular cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Qing‐Yu He,et al.  Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead. , 2007, European journal of pharmacology.

[35]  C. Orvig,et al.  Boon and Bane of Metal Ions in Medicine , 2003, Science.

[36]  Dik‐Lung Ma,et al.  Bis-intercalative dinuclear platinum(II) 6-phenyl-2,2′-bipyridine complexes exhibit enhanced DNA affinity but similar cytotoxicity compared to the mononuclear unit , 2003, JBIC Journal of Biological Inorganic Chemistry.

[37]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[38]  C. Shaw,et al.  Gold-Based Therapeutic Agents , 1999 .

[39]  J. M. Pratt,et al.  Cytotoxicity of 2,2':6',2' '-terpyridineplatinum(II) complexes against human ovarian carcinoma. , 1999, Journal of medicinal chemistry.

[40]  P. Sadler,et al.  Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. , 2005, Chemical communications.

[41]  Qing‐Yu He,et al.  Gold(III) Porphyrin 1a Induced Apoptosis by Mitochondrial Death Pathways Related to Reactive Oxygen Species , 2005 .

[42]  J. Reedijk.  Improved understanding in platinium antitumour chemistry , 1996 .

[43]  L. Messori,et al.  Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. , 2000, Journal of medicinal chemistry.

[44]  R. Schirmer,et al.  Human thioredoxin reductase is efficiently inhibited by (2,2':6',2' '-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. , 2001, Journal of medicinal chemistry.

[45]  S. Fan,et al.  Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma , 2006, International journal of cancer.

[46]  Simon Parsons,et al.  Protein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Che,et al.  Novel luminescent cyclometaiated and terpyridine gold(III) complexes and DNA binding studies , 1995 .

[48]  Dik‐Lung Ma,et al.  Water soluble luminescent platinum terpyridine complexes with glycosylated acetylide and arylacetylide ligands: photoluminescent properties and cytotoxicities. , 2005, Chemical communications.

[49]  T. Kiss,et al.  Interactions of VO(IV) with oligopeptides , 2003 .

[50]  L. Messori,et al.  Mechanisms of cytotoxicity of selected organogold(III) compounds. , 2005, Journal of medicinal chemistry.

[51]  C. Che,et al.  Physiologically stable vanadium(IV) porphyrins as a new class of anti-HIV agents. , 2005, Chemical communications.

[52]  D. Mingos,et al.  Multidimensional crystal engineering of bifunctional metal complexes containing complementary triple hydrogen bonds , 1995 .

[53]  P. Sadler,et al.  Metals in Medicine. , 1999, Angewandte Chemie.

[54]  Jan Reedijk,et al.  New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Bumann,et al.  The effect of desferrioxamine on cell proliferation in human tumour cell lines. , 1991, Toxicology in vitro : an international journal published in association with BIBRA.

[56]  S. Lippard,et al.  Synthesis and structure of a bis[terpyridineplatinum(II)] complex and its evaluation as a metallointercalator , 1980 .

[57]  L. Ronconi,et al.  Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity. , 2005, Inorganic chemistry.

[58]  Dik‐Lung Ma,et al.  Synthesis and Biological Activity of a Platinum(II) 6‐Phenyl‐2,2′‐bipyridine Complex and Its Dimeric Analogue , 2003, Chembiochem : a European journal of chemical biology.

[59]  E. Kodama,et al.  Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. , 2003, Antiviral research.

[60]  A. Bishayee,et al.  Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted by phenobarbital. , 1995, British Journal of Cancer.

[61]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[62]  C. Che,et al.  Platinum(II) Complexes of Dipyridophenazine as Metallointercalators for DNA and Potent Cytotoxic Agents against Carcinoma Cell Lines , 1999 .

[63]  L. Que,et al.  Dioxygen activation at mononuclear nonheme iron active sites: enzymes, models, and intermediates. , 2004, Chemical reviews.

[64]  E. Beutler.  History of iron in medicine. , 2002, Blood cells, molecules & diseases.

[65]  S. Lippard,et al.  Metallointercalation reagents. 2-hydroxyethanethiolato(2,2',2'-terpyridine)-platinum(II) monocation binds strongly to DNA by intercalation. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[66]  H. Gray.  Biological inorganic chemistry at the beginning of the 21st century , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Achim Müller,et al.  Polyoxometalate Chemistry: An Old Field with New Dimensions in Several Disciplines , 1991 .

[68]  Dik‐Lung Ma,et al.  A bifunctional platinum(II) complex capable of intercalation and hydrogen-bonding interactions with DNA: binding studies and cytotoxicity. , 2003, Chemistry.

[69]  L. Messori,et al.  Structure and DNA binding properties of the gold(III) complex (AuCl2(esal)) , 1999 .

[70]  S. Lippard.  The inorganic side of chemical biology , 2006, Nature chemical biology.

[71]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[72]  C. Che,et al.  Highly cytotoxic iron(II) complexes with pentadentate pyridyl ligands as a new class of anti-tumor agents. , 2005, Chemical communications.

[73]  L. Stowe.  THE JOURNAL: I , 1922 .

[74]  Dik‐Lung Ma,et al.  DNA binding and cytotoxicity of ruthenium(II) and rhenium(I) complexes of 2-amino-4-phenylamino-6-(2-pyridyl)-1,3,5-triazine. , 2007, Inorganic chemistry.

[75]  M. Braña,et al.  Intercalators as anticancer drugs. , 2001, Current pharmaceutical design.

[76]  S. Lippard,et al.  Metallointercalation reagents. Synthesis, characterization, and structural properties of thiolato(2,2',2''-terpyridine)platinum(II) complexes , 1976 .

[77]  N. Luedtke,et al.  Eilatin Ru(II) Complexes Display Anti‐HIV Activity and Enantiomeric Diversity in the Binding of RNA , 2002, Chembiochem : a European journal of chemical biology.

[78]  A. Evangelou,et al.  Synthetic Analogues for Oxovanadium(IV)–Glutathione Interaction: An EPR, Synthetic and Structural Study of Oxovanadium(IV) Compounds with Sulfhydryl‐Containing Pseudopeptides and Dipeptides , 1999 .

[79]  C. Che,et al.  Syntheses of ruthenium(II) quinonediimine complexes of cyclam and characterization of their DNA-binding activities and cytotoxicity. , 2002, Inorganic chemistry.

[80]  L. Mir,et al.  Bleomycin: revival of an old drug. , 1996, General pharmacology.

[81]  Jim A. Thomas,et al.  Kinetically inert transition metal complexes that reversibly bind to DNA. , 2003, Chemical Society reviews.

[82]  R. Schinazi,et al.  Polyoxometalates in Medicine. , 1998, Chemical reviews.

[83]  Ilme Schlichting,et al.  Structure and chemistry of cytochrome P450. , 2005, Chemical reviews.

[84]  P. Sadler,et al.  Medicinal Inorganic Chemistry , 1999 .

[85]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.